Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619495 · ClinicalTrials.gov registry record
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 120,000
- Enrollment target
NCT07619495 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 120,000 participants.
The verdict
NCT07619495 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 120,000 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Interventions
- DRUG Semaglutide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120,000 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07619495
The ClinicalTrials.gov registry entry for NCT07619495 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT07619495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07619495 about?
NCT07619495 is a clinical study titled "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07619495?
This trial is currently completed. The enrollment target is 120,000 participants. The study started on 2026-01-20. Estimated completion is 2026-06-01.
What interventions are being tested in trial NCT07619495?
The interventions under investigation include: Semaglutide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07619495?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.